Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study
Christiane Pott(University Hospital Schleswig-Holstein), Martin Dreyling(LMU Klinikum), Sebastian Böttcher(University Hospital Schleswig-Holstein), Vincent Ribrag(Institut Gustave Roussy), Eva Hoster(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Achiel L. van Hoof(AZ Sint-Jan), Hanneke C. Kluin‐Nelemans(University Medical Center Groningen), Anne Plonquet(Inserm), Vahid Asnafi(Hôpital Necker-Enfants Malades), Jan Walewski(The Maria Sklodowska-Curie National Research Institute of Oncology), Michael Kneba(Universitäts Hautklinik Kiel), Jacques J. M. van Dongen(Universidad de Salamanca), Evelyne Callet‐Bauchu(Hôpital Lyon Sud), Elizabeth Macintyre(Inserm), Marie‐Hélène Delfau‐Larue(Inserm), Kheïra Beldjord(Inserm), Peter Dreger(Heidelberg University), Marek Trněný(Charles University), Reiner Siebert(Universität Ulm), Françoise Berger(Hôpital Lyon Sud), Wolfgang Hiddemann(Christian-Albrechts-Universität zu Kiel), Michael Unterhalt, Olivier Hermine(Centre National de la Recherche Scientifique), Niels Smedegaard Andersen(Rigshospitalet)
Cited by 269
Related Papers
<i>LMO2</i> -Associated Clonal T Cell Proliferation in Two Patients after Gene Therapy for SCID-X1
|Science|2003|3.5k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1
|Journal of Clinical Investigation|2008|1.8k